RUNDC3B

Summary

RUNDC3B (RUN domain containing 3B, HGNC:30286) is a protein-coding gene on chromosome 7q21.12, encoding RUN domain-containing protein 3B (Q96NL0).

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 30 total
• MANE Select transcript: NM_001134405

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30286
Approved symbol	RUNDC3B
Name	RUN domain containing 3B
Location	7q21.12
Locus type	gene with protein product
Status	Approved
Aliases	RPIP9, RPIB9
Ensembl gene	ENSG00000105784
Ensembl biotype	protein_coding
OMIM	617295
Entrez	154661

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 4 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000312373, ENST00000338056, ENST00000394654, ENST00000466676, ENST00000476114, ENST00000489461, ENST00000493037, ENST00000496000, ENST00000497788, ENST00000878331, ENST00000878332, ENST00000878333, ENST00000878334, ENST00000878335, ENST00000878336, ENST00000878337, ENST00000961225

RefSeq mRNA: 8 — MANE Select: NM_001134405 NM_001134405, NM_001134406, NM_001394224, NM_001394225, NM_001394226, NM_001394227, NM_001394228, NM_138290

CCDS: CCDS47635, CCDS47636, CCDS5609

Canonical transcript exons

ENST00000394654 — 11 exons

Exon	Start	End
ENSE00000701940	87807373	87807519
ENSE00001814162	87829885	87832296
ENSE00001909790	87628398	87628945
ENSE00003458698	87710570	87710655
ENSE00003522481	87650822	87650937
ENSE00003545712	87816141	87816262
ENSE00003605604	87739791	87739880
ENSE00003623455	87741499	87741579
ENSE00003640494	87770581	87770749
ENSE00003644309	87700421	87700554
ENSE00003657746	87777798	87777955

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 98.15.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7252 / max 33.7347, expressed in 228 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79398	0.4119	170
79400	0.2294	106
79399	0.0838	46

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.15	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.76	gold quality
secondary oocyte	CL:0000655	95.65	gold quality
buccal mucosa cell	CL:0002336	94.02	gold quality
middle temporal gyrus	UBERON:0002771	93.75	gold quality
oocyte	CL:0000023	93.04	gold quality
cortical plate	UBERON:0005343	93.00	gold quality
primary visual cortex	UBERON:0002436	90.82	gold quality
cerebellar vermis	UBERON:0004720	90.78	gold quality
entorhinal cortex	UBERON:0002728	90.66	gold quality
pons	UBERON:0000988	90.57	gold quality
postcentral gyrus	UBERON:0002581	90.20	gold quality
superior frontal gyrus	UBERON:0002661	89.92	gold quality
parietal lobe	UBERON:0001872	89.41	gold quality
paraflocculus	UBERON:0005351	89.00	gold quality
occipital lobe	UBERON:0002021	88.90	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.74	gold quality
Brodmann (1909) area 10	UBERON:0013541	88.64	gold quality
substantia nigra pars compacta	UBERON:0001965	88.13	gold quality
frontal pole	UBERON:0002795	87.90	gold quality
superior vestibular nucleus	UBERON:0007227	87.50	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.37	gold quality
substantia nigra pars reticulata	UBERON:0001966	86.96	gold quality
right adrenal gland cortex	UBERON:0035827	86.58	gold quality
adrenal cortex	UBERON:0001235	86.15	gold quality
jejunal mucosa	UBERON:0000399	86.06	gold quality
right adrenal gland	UBERON:0001233	86.03	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.64	gold quality
cerebellum	UBERON:0002037	85.62	gold quality
left adrenal gland cortex	UBERON:0035825	85.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10137	yes	4.50
E-ANND-3	no	5.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

146 targeting RUNDC3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197

Literature-anchored findings (GeneRIF, showing 4)

• During a large-scale screen of a human fetal brain cDNA library, a full-length cDNA encoding a novel Rap2-interacting protein was isolated and sequenced. The gene was mapped to human chromosome 7q21-q22 and has 9 exons and 8 introns. (PMID:12645870)
• activation of Rap2-binding protein 9 (RPIP9) occurs during the malignant breast epithelial transformation and increases with progression toward an invasive phenotype (PMID:15986426)
• The ABCB1 nested gene RUNDC3B expression, although upregulated by TSA, is independent of the ABCB1 alternative promoter used. (PMID:22846052)
• RUNDC3B expression has a role in promoter methylation in lymphoid malignancies (PMID:26011749)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	rundc3b	ENSDARG00000009961
mus_musculus	Rundc3b	ENSMUSG00000040570
rattus_norvegicus	Rundc3b	ENSRNOG00000008463
drosophila_melanogaster	CG6051	FBGN0039492
drosophila_melanogaster	CG31064	FBGN0051064
caenorhabditis_elegans		WBGENE00003084

Paralogs (13): RUFY3 (ENSG00000018189), ZFYVE16 (ENSG00000039319), SNX29 (ENSG00000048471), ZFYVE26 (ENSG00000072121), RUNDC3A (ENSG00000108309), PLEKHM2 (ENSG00000116786), ZFYVE28 (ENSG00000159733), ZFYVE1 (ENSG00000165861), ZFYVE19 (ENSG00000166140), PLEKHF1 (ENSG00000166289), PLEKHF2 (ENSG00000175895), RUFY1 (ENSG00000176783), RUFY2 (ENSG00000204130)

Protein

Protein identifiers

RUN domain-containing protein 3B — Q96NL0 (reviewed: Q96NL0)

Alternative names: Rap2-binding protein 9, Rap2-interacting protein 9

All UniProt accessions (1): Q96NL0

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with RAP2A.

Tissue specificity. Isoform 2 is expressed at high levels in brain, thymus, ovary, testis, leukocyte, liver, small intestine and prostate. Isoform 1 is expressed in the brain, testis and adrenal gland. It is activated in tumorigenic breast cancer cell lines and in the primary tumor of breast cancer patients. Activation also correlates with metastatic lymph node invasion and can be detected in metastatic epithelial cells from the lymph nodes and in the bone marrow of patients.

Similarity. Belongs to the RUNDC3 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q96NL0-1	1	yes
Q96NL0-2	2
Q96NL0-3	3
Q96NL0-4	4
Q96NL0-5	5

RefSeq proteins (8): NP_001127877, NP_001127878, NP_001381153, NP_001381154, NP_001381155, NP_001381156, NP_001381157, NP_612147 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004012	Run_dom	Domain
IPR037213	Run_dom_sf	Homologous_superfamily
IPR047339	RUN_RUNDC3B	Domain
IPR047340	RUNDC3A_B	Family

Pfam: PF02759

UniProt features (23 total): splice variant 5, sequence conflict 5, sequence variant 3, modified residue 3, region of interest 2, compositionally biased region 2, chain 1, domain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NL0-F1	68.84	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 13, 232, 233

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 183 (showing top): RNGTGGGC_UNKNOWN, GOZGIT_ESR1_TARGETS_DN, BOYAULT_LIVER_CANCER_SUBCLASS_G12_DN, SCHLOSSER_SERUM_RESPONSE_DN, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, SABATES_COLORECTAL_ADENOMA_DN, KIM_WT1_TARGETS_12HR_UP, NOUZOVA_METHYLATED_IN_APL, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP, CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, DODD_NASOPHARYNGEAL_CARCINOMA_DN, ZHAN_MULTIPLE_MYELOMA_MS_UP, BROWNE_HCMV_INFECTION_48HR_UP, KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_UP

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

568 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RUNDC3B	RAP2A	P10114	777
RUNDC3B	SLC25A40	Q8TBP6	662
RUNDC3B	TMEM243	Q9BU79	582
RUNDC3B	DMTF1	Q9Y222	572
RUNDC3B	CROT	Q9UKG9	538
RUNDC3B	ADAM22	Q9P0K1	492
RUNDC3B	DBF4	Q9UBU7	484
RUNDC3B	ABCB1	P08183	475
RUNDC3B	CRISPLD1	Q9H336	449
RUNDC3B	PCDHGA12	O60330	447
RUNDC3B	ABCB4	P21439	418
RUNDC3B	KCTD20	Q7Z5Y7	405
RUNDC3B	SCN4B	Q8IWT1	398
RUNDC3B	TEX47	Q8TBZ9	396
RUNDC3B	SH3YL1	Q96HL8	388

IntAct

9 interactions, top by confidence:

A	B	Type	Score
CSNK1G2	RUNDC3B	psi-mi:“MI:0915”(physical association)	0.550
RUNDC3B	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.370
DYNC1I1	RUNDC3B	psi-mi:“MI:0915”(physical association)	0.370
CSNK1G2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
VPS35	KIF2A	psi-mi:“MI:0914”(association)	0.350
RUNDC3A	GMNN	psi-mi:“MI:0914”(association)	0.350
RUNDC3A	AP2A1	psi-mi:“MI:0914”(association)	0.350
STK3	THAP12	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): RUNDC3B (Affinity Capture-MS), RUNDC3B (Affinity Capture-MS), RUNDC3B (Affinity Capture-MS), RUNDC3B (Affinity Capture-MS), RUNDC3B (Proximity Label-MS), RUNDC3B (Affinity Capture-MS), RUNDC3B (Negative Genetic), RUNDC3B (Affinity Capture-RNA), RUNDC3B (Two-hybrid), RUNDC3B (Two-hybrid), RUNDC3B (Two-hybrid), RUNDC3B (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GUX5, A0A571BF63, A0A8M9QN10, A1L1K1, A2ARM1, A2AVJ5, A7YDW0, O08576, O60268, P0C6P5, P97433, Q08E29, Q0V9V7, Q0VDN7, Q17QK1, Q2NKQ1, Q2NL11, Q3B7K9, Q3SYZ9, Q4R7B9, Q561Q8, Q59EK9, Q5E9L4, Q5E9R0, Q5EB20, Q5NVC2, Q5PQS0, Q5R565, Q5U3W3, Q5XHG1, Q61194, Q6AYK4, Q6MZQ0, Q6NXJ0, Q6P7D5, Q6PDC0, Q6ZUJ8, Q80ZQ3, Q8BPQ7, Q8N1W1

Diamond homologs: A7YDW0, O08576, Q08E29, Q0V9V7, Q17QK1, Q3B7K9, Q4R7B9, Q59EK9, Q5FVJ0, Q5NVC2, Q5R4V2, Q5R565, Q5R5R4, Q5U3W3, Q6PDC0, Q7L099, Q8BIJ7, Q8R4C2, Q8WXA3, Q96NL0, Q96T51, Q9D394, B1AVY7, Q08DX0, Q559T8, Q5PQS0, Q5R7A7, Q7TSI1, Q80TQ5, Q8IUI4, Q8IWE5, Q8R4V0, Q8TEQ0, Q96BR1, Q96L93, Q9D3S3, Q9ERE3, Q9VB25, Q9Y4G2, A2RSQ0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2467 predictions. Top by Δscore:

Variant	Effect	Δscore
7:87628941:TGCAG:T	donor_loss	1.0000
7:87628942:GCAGG:G	donor_loss	1.0000
7:87628944:AG:A	donor_loss	1.0000
7:87628945:GG:G	donor_loss	1.0000
7:87650819:T:G	acceptor_gain	1.0000
7:87650819:TA:T	acceptor_loss	1.0000
7:87650820:A:AG	acceptor_gain	1.0000
7:87650820:AGGTT:A	acceptor_loss	1.0000
7:87650821:G:GG	acceptor_gain	1.0000
7:87650933:AAAAG:A	donor_loss	1.0000
7:87650934:AAAG:A	donor_loss	1.0000
7:87650935:AAGGT:A	donor_loss	1.0000
7:87650936:AGG:A	donor_loss	1.0000
7:87650938:GTAA:G	donor_loss	1.0000
7:87650939:T:G	donor_loss	1.0000
7:87694038:T:G	donor_gain	1.0000
7:87739787:TTA:T	acceptor_loss	1.0000
7:87739789:A:AT	acceptor_loss	1.0000
7:87739789:AG:A	acceptor_gain	1.0000
7:87739790:GG:G	acceptor_gain	1.0000
7:87739790:GGA:G	acceptor_gain	1.0000
7:87739790:GGAGA:G	acceptor_gain	1.0000
7:87739876:TTCAG:T	donor_loss	1.0000
7:87739877:TCAG:T	donor_loss	1.0000
7:87739878:CAG:C	donor_loss	1.0000
7:87739879:AG:A	donor_loss	1.0000
7:87739880:GGT:G	donor_loss	1.0000
7:87739881:G:C	donor_loss	1.0000
7:87739882:T:A	donor_loss	1.0000
7:87741497:A:AG	acceptor_gain	1.0000

AlphaMissense

2993 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:87628930:T:C	L36P	1.000
7:87650839:T:C	L47P	1.000
7:87700462:T:A	W111R	1.000
7:87700462:T:C	W111R	1.000
7:87710579:T:A	W145R	1.000
7:87710579:T:C	W145R	1.000
7:87710595:T:A	L150H	1.000
7:87710595:T:C	L150P	1.000
7:87710604:A:T	K153I	1.000
7:87777943:T:C	L332P	1.000
7:87777955:T:C	L336P	1.000
7:87628941:T:C	C40R	0.999
7:87700464:G:C	W111C	0.999
7:87700464:G:T	W111C	0.999
7:87700481:C:A	A117D	0.999
7:87700485:C:G	C118W	0.999
7:87700554:G:C	K141N	0.999
7:87700554:G:T	K141N	0.999
7:87710570:G:C	G142R	0.999
7:87710571:G:A	G142D	0.999
7:87710577:C:A	A144D	0.999
7:87710595:T:G	L150R	0.999
7:87710631:C:A	A162D	0.999
7:87739798:T:G	Y173D	0.999
7:87739853:T:C	L191P	0.999
7:87739862:T:A	L194H	0.999
7:87739862:T:C	L194P	0.999
7:87777946:A:C	Q333P	0.999
7:87650839:T:A	L47Q	0.998
7:87650839:T:G	L47R	0.998

dbSNP variants (sampled 300 via entrez): RS1000002062 (7:87660379 A>G), RS1000039130 (7:87685323 A>C,G), RS1000056048 (7:87660063 T>C), RS1000059993 (7:87772170 A>T), RS1000079458 (7:87706794 A>G), RS1000087240 (7:87678177 T>C), RS1000092742 (7:87631396 T>C), RS1000113261 (7:87771864 A>T), RS1000137371 (7:87739992 T>G), RS1000141390 (7:87828634 C>A), RS1000155236 (7:87786640 A>G), RS1000162630 (7:87650382 T>C), RS1000177536 (7:87692641 T>C,G), RS1000183002 (7:87705208 T>C), RS1000190757 (7:87698200 C>A,T)

Disease associations

OMIM: gene MIM:617295 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002279_71	PR interval in Tripanosoma cruzi seropositivity	1.000000e-06
GCST003101_4	Bone mineral density (spine) and age at menarche	9.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004462	PR interval
EFO:0004703	age at menarche
EFO:0007701	spine bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs28656907	Dosage	3	imatinib	Drug Toxicity;Gastrointestinal Stromal Tumors

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3747802	ABCB1, RUNDC3B		0.00	0
rs10267099	ABCB1, RUNDC3B	3	1.50	1	atenolol
rs17160359	ABCB1, RUNDC3B	3	0.00	1	capecitabine;fluorouracil
rs28656907	ABCB1, RUNDC3B	3	0.00	1	imatinib

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	11
Benzo(a)pyrene	decreases expression, increases methylation	4
Aflatoxin B1	affects expression, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
bisphenol A	decreases methylation	1
terbufos	increases methylation	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
potassium chromate(VI)	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
coumarin	increases phosphorylation	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, increases expression, affects cotreatment	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Cadmium	decreases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Fonofos	increases methylation	1
Estradiol	decreases expression	1
Formaldehyde	increases expression	1
Naphthoquinones	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety